About Synaptopodin-2
Synaptopodin-2 (SYNPO2) is a protein
from Homo sapiens identified by UniProt accession
Q9UMS6, 1093 residues long.
MolForge cross-references it against 0 known binders and
172 disease associations.
Target properties
| Protein name | Synaptopodin-2 |
|---|
| UniProt accession | Q9UMS6 |
|---|
| Gene | SYNPO2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1093 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (172)
Diseases linked to this target (Open Targets).
- diastolic blood pressure · score 0.37
- neurodegenerative disease · score 0.37
- malignant epithelial tumor of ovary · score 0.36
- heel bone mineral density · score 0.14
- aortic vascular smooth muscle cell calcification measurement · score 0.12
- appendicular lean mass · score 0.12
- Blackfan-Diamond anemia · score 0.07
- bladder transitional cell carcinoma · score 0.06
- breast cancer · score 0.06
- primary familial polycythemia due to EPO receptor mutation · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UMS6-F1 | alphafold | PREDICTED | 49.52 | — |
Amino-acid sequence (1093 residues)
MGTGDFICIS MTGGAPWGFR LQGGKEQKQP LQVAKIRNQS KASGSGLCEG DEVVSINGNP CADLTYPEVI KLMESITDSL QMLIKRPSSG ISEALISENE NKNLEHLTHG GYVESTTLQI RPATKTQCTE FFLAPVKTEV PLAENQRSGP DCAGSLKEET GPSYQRAPQM PDSQRGRVAE ELILREKVEA VQPGPVVELQ LSLSQERHKG ASGPLVALPG AEKSKSPDPD PNLSHDRIVH INSIPTNEKA DPFLRSSKII QISSGRELRV IQESEAGDAG LPRVEVILDC SDRQKTEGCR LQAGKECVDS PVEGGQSEAP PSLVSFAVSS EGTEQGEDPR SEKDHSRPHK HRARHARLRR SESLSEKQVK EAKSKCKSIA LLLTDAPNPN SKGVLMFKKR RRRARKYTLV SYGTGELERE ADEEEEGDKE DTCEVAFLGA SESEVDEELL SDVDDNTQVV NFDWDSGLVD IEKKLNRGDK MEMLPDTTGK GALMFAKRRE RMDQITAQKE EDKVGGTPSR EQDAAQTDGL RTTTSYQRKE EESVRTQSSV SKSYIEVSHG LGHVPQQNGF SGTSETANIQ RMVPMNRTAK PFPGSVNQPA TPFSPTRNMT SPIADFPAPP PYSAVTPPPD AFSRGVSSPI AGPAQPPPWP QPAPWSQPAF YDSSERIASR DERISVPAKR TGILQEAKRR STTKPMFTFK EPKVSPNPEL LSLLQNSEGK RGTGAGGDSG PEEDYLSLGA EACNFMQSSS AKQKTPPPVA PKPAVKSSSS QPVTPVSPVW SPGVAPTQPP AFPTSNPSKG TVVSSIKIAQ PSYPPARPAS TLNVAGPFKG PQAAVASQNY TPKPTVSTPT VNAVQPGAVG PSNELPGMSG RGAQLFAKRQ SRMEKYVVDS DTVQAHAARA QSPTPSLPAS WKYSSNVRAP PPVAYNPIHS PSYPLAALKS QPSAAQPSKM GKKKGKKPLN ALDVMKHQPY QLNASLFTFQ PPDAKDGLPQ KSSVKVNSAL AMKQALPPRP VNAASPTNVQ ASSVYSVPAY TSPPSFFAEA SSPVSASPVP VGIPTSPKQE SASSSYFVAP RPKFSAKKSG VTIQVWKPSV VEE
Explore Synaptopodin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets